Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith discusses the company's latest quarterly report with Proactive's Stephen Gunnion, highlighting significant progress in the drug development group's two phase II clinical trials. These trials include the chemotherapy-induced peripheral neuropathy and endometriosis studies, where Ananda is nearing the final stages before drug manufacturing and delivery to Edinburgh University. Sturgess-Smith also discussed the ongoing work on drug stability, ensuring consistent CBD levels.
He expressed optimism about the productivity of the quarter, noting that the company is now firmly focused on executing its strategy. Additionally, he provided updates on a preclinical study using HFpEF (heart failure with preserved ejection fraction) in mice, outlining plans for more extensive trials aimed at translating these results into human studies.
Sturgess-Smith also discussed Ananda's recent decision to join the Cannabinoid Research and Development Group, which aims to advance clinical trials using cannabinoids. He emphasised the importance of moving into traditional pharmaceutical routes, especially in the UK.
Furthermore, the company has published a white paper titled "An Introduction to Cannabidiol as a Pharmaceutical Medicine," aimed at those interested in CBD’s potential as a drug.
